Vista Pharmaceuticals (524711) Q1 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended June 30, 2025, and scheduled the 34th AGM for September 30, 2025, via video conferencing.

• Re-appointments of key directors, including Managing Director and Whole Time Directors, were recommended for new three-year terms, subject to shareholder approval.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹151.88 lakhs, down from ₹179.50 lakhs in Q1 FY25.

• Loss before tax for the quarter was ₹148.01 lakhs, compared to a profit before tax of ₹117.13 lakhs in the same quarter last year.

• Net loss for the quarter stood at ₹129.04 lakhs, versus a net loss of ₹85.70 lakhs year-over-year.

• Basic and diluted EPS for the quarter were both -₹0.22, compared to -₹0.15 in the prior year quarter.

Outlook and guidance

• Board approved convening the AGM and re-appointments, indicating continuity in leadership and governance.